DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

April 26 2018 Women and girls of childbearing potential must no longer take valproate medicines...

  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:11
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:42
  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08
  • Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Women of childbearing potential must be on Pregnancy Prevention Programme if taking valproate

    Thursday, 26 April 2018 11:48

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

diabetes4April 6 2016

An association between the diabetes drug pioglitazone and increased risk of bladder cancer has been identified in a new study. It found no similar risk with rosiglitazone.

The findings published in the British Medical Journal suggest that the risk increases with increasing duration of treatment and higher dose. While the number of patients likely to be affected is small, the effect is significant, so should be taken into consideration when assessing overall risks and benefits of the therapy, the researchers have advised.

Researchers analysed data for over 145,000 patients being treated for diabetes between 2000 and 2013. The data had been supplied by GPs to the UK Clinical Practice Research Datalink. Combined, and the accessed records amounted to nearly 700,000 person years of follow up.

From this, the study identified 622 patients as being newly diagnosed with bladder cancer, equivalent to a crude incidence of 90.2 per 100,000 person years. Pioglitazone was identified with an increased risk of bladder cancer, at 121.0 per 100,000 person years, compared to an average of 88.9 per 100,000 person years where pioglitazone was not used.

It equates to an overall 63% increased risk of incident bladder cancer, said the researchers. Rosiglitazone had a similar level of risk to non exposure at 86.2 compared to 88.9 per 100,000 person years.

The difference between the two glitazone drugs suggest the difference “is drug specific and not a class effect,” they concluded. Both pioglitazone and rosiglitazone entered the UK market in 2000 and were intended for the same target population. “Given their similarities, it is unlikely that confounding by indication or detection bias can explain the association observed with pioglitazone.

“Of note, although the biological mechanism for pioglitazone induced bladder cancer is not clear, this imbalance in the risk of bladder cancer between these two thiazolidinediones could likely be explained by pharmacological differences.”

The researchers point out that pioglitzaone has dual activity on the peroxisome proliferator activated receptors (PPAR) α and γ, while rosiglitazone is only active at PPAR γ.
“Although differences in PPAR activity are possible explanations for the observed association, additional studies are needed to better understand the biological mechanism behind the possible pioglitazone specific effect on the bladder.”

A second study, also published in the same issue of the BMJ has looked at diabetes medicines, particularly gliptins and glitazones, and the relationship to the risks of amputation, blindness, severe kidney failure, hyperglycaemia and hypoclycaemia.

This time the researchers assessed data from the QResearch database used in 1,243 GP practices in England, and covering almost 470,000 adults with type 2 diabetes between 2007 and 2015. The analysis found that 21,308 (4.5%) patients received prescriptions for glitazones and 32,533 (6.9%) received prescriptions for gliptins. It also looked at whether the drugs were given as monotherapy or in combination.

Findings included:

  • there were significantly lower risks of hyperglycaemia among patients prescribed dual therapy involving metformin with either gliptins or glitazones compared with metformin monotherapy;
  • triple therapy with metformin, sulphonylureas, and either gliptins or glitazones was associated with significantly higher risks of hypoglycaemia than those prescribed metformin monotherapy, but these risks were similar to those involving dual therapy with metformin and sulphonylureas;
  • triple therapy with metformin, sulphonylureas, and glitazones was associated with a significantly reduced risk of blindness compared with metformin monotherapy.

Commenting on both studies, the BMJ said: “Both studies are observational so no firm conclusions can be drawn about cause and effect. However, the researchers say these results may have implications for prescribing, and suggest doctors and patients should be aware when assessing the overall risks and benefits of diabetes drugs.”

Links:

BMJ announcement

M Tuccori et al. ‘Pioglitazone use and risk of bladder cancer: population based cohort study’. BMJ 2016; 352: i1541

J Hippisley-Cox and C Coupland. ‘Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care’. BMJ 2016; 352: i1450

Clinical News

July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued.
July 20 2018 A consultation asking for views on how the safety features required under the Falsified Medicines Directive should be implemented has been issued. The MHRA has launched the consultation with...